Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.48 |
| ▸ | CA1 | P00915 | 19/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | MMP9 | P14780 | 4/20 | 0.48 |
| ▸ | MMP8 | P22894 | 4/20 | 0.48 |
| ▸ | MMP13 | P45452 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233445 | 0.98 | CA2 (0.46) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2231262 | 0.98 | CA2 (0.46) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2232023 | 0.98 | CA2 (0.46) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL107276 | 0.93 | CA2 (0.58) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2231136 | 0.92 | CA2 (0.50) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL548088 | 0.92 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2234024 | 0.91 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2232614 | 0.91 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2230675 | 0.91 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2230869 | 0.90 | CA2 (0.48) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834251-B1 | IONIC COMPOUNDS HAVING A SILYLOXY GROUP | HYDRO QUEBEC (CA) | 2019-11-13 | — | — | EP | claimed |
| US-9969757-B2 | Ionic compounds having a silyloxy group | HYDRO-QUEBEC (CA) | 2018-05-15 | — | — | US | claimed |
| EP-2602307-B1 | LUBRICANT COMPOSITION WITH RUST INHIBITING PROPERTIES AND WITH AN IONIC LIQUID AS THE BASE OIL | KYODO YUSHI (JP) | 2017-05-10 | — | — | EP | claimed |
| US-9012381-B2 | Lubricant composition using ionic liquid as a base oil and having excellent rust prevention properties | KYODO YUSHI CO., LTD. (JP) | 2015-04-21 | — | — | US | claimed |
| US-20150093655-A1 | IONIC COMPOUNDS HAVING A SILYLOXY GROUP | HYDRO-QUEBEC (CA) | 2015-04-02 | — | — | US | claimed |
| EP-2602307-A1 | LUBRICANT COMPOSITION WITH EXCELLENT RUST INHIBITING PROPERTIES AND WITH AN IONIC LIQUID AS A BASE OIL | Kyodo Yushi Co., Ltd. (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20130137615-A1 | LUBRICANT COMPOSITION USING IONIC LIQUID AS BASE OIL AND HAVING EXCELLENT RUST PREVENTION PROPERTIES | KYODO YUSHI CO., LTD. (JP) | 2013-05-30 | — | — | US | claimed |
| CN-110800150-B | Non-aqueous electrolyte and electrolytic solution containing electrolyte stabilizing material, secondary battery containing the same, and use thereof | 株式会社村田制作所 | 2022-11-29 | — | — | CN | disclosed |
| US-11355782-B2 | Electrolytic solution for secondary batteries, secondary battery, battery pack, electric vehicle, electric power storage system, electric power tool, and electronic device | MURATA MANUFACTURING CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3955346-A1 | SECONDARY BATTERY | Murata Manufacturing Co., Ltd. (JP) | 2022-02-16 | — | — | EP | disclosed |
| EP-3560012-B1 | BIPOLAR SECONDARY BATTERY, AS WELL AS BATTERY PACK, ELECTRIC VEHICLE, ELECTRIC POWER STORAGE SYSTEM, ELECTRIC POWER TOOL, AND ELECTRONIC APPARATUS COMPRISING THE SAME | MURATA MANUFACTURING CO (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3666860-A1 | ANTI-FLAKING AGENT AND LUBRICANT COMPOSITION COMPRISING THE SAME | Kyodo Yushi Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-20200161707-A1 | ELECTROLYTIC SOLUTION FOR SECONDARY BATTERIES, SECONDARY BATTERY, BATTERY PACK, ELECTRIC VEHICLE, ELECTRIC POWER STORAGE SYSTEM, ELECTRIC POWER TOOL, AND ELECTRONIC DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-7666574-B2 | Positive resist composition and pattern forming method | FUJIFILM CORPORATION (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7635554-B2 | Positive resist composition and pattern forming method | FUJIFILM CORPORATION (JP) | 2009-12-22 | — | — | US | disclosed |
| US-20080248421-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080241746-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2008-10-02 | — | — | US | disclosed |
| US-20080081292-A1 | RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20010044534-A1 | Pyrimidine derivative salt | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-11-22 | — | — | US | disclosed |
| US-20010031875-A1 | Optically active ionic liquid | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150093655-A1 | IONIC COMPOUNDS HAVING A SILYLOXY GROUP | EPCAM, ILK, VIM | CA2 105/4885CA1 99/4885MMP1 1486/4885 |
| US-20010031875-A1 | Optically active ionic liquid | IK, INF2, ICMT | CA2 218/4885CA1 1040/4885MMP1 2398/4885 |
| US-20010044534-A1 | Pyrimidine derivative salt | TYMS, RTF2, UMPS | CA2 2702/4885CA1 3747/4885MMP1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.